INTRODUCTION
Hepatic steatosis is a common complication of obesity and is characterized by excess accumulation of triglyceride (TG) in hepatocytes. Multiple pathways contribute to steatosis and include fatty acid (FA) influx into the liver, increased de novo FA synthesis or de novo lipogenesis (DNL), decreased FA oxidation and reduced secretion of very low density lipoproteins (VLDL) (1, 2) .
CD36 is a class B scavenger receptor that plays an important role in several pathways of FA utilization. The protein is expressed in many cell types including lingual taste bud cells, enterocytes, adipocytes, myocytes and immune cells. On taste bud cells CD36 is important for FA recognition and fat perception (3, 4) . In skeletal muscle, heart and adipose tissue, CD36
facilitates tissue FA uptake and utilization (5, 6) . In the small intestine it is important for chylomicron secretion (7) and for FA-induced release of secretin and cholecystokinin (8) . In the liver, CD36 is expressed on endothelial, parenchymal and Kupffer cells (9) . Basal expression of liver CD36 is low but increases in experimental models of hepatic steatosis such as genetic obesity and high fat feeding (10, 11) or following activation of the pro-steatotic transcription factors, LXR, PXR and AHR (Liver, pregnane X receptors and aryl hydrocarbon receptor) by xenobiotics, bacteria or cytokines (12) . Mice fed a high fat diet have increased liver CD36 expression associated with enhanced hepatic FA uptake and TG accumulation and these are prevented by CD36 deletion (11) . Interestingly, however, the pro-steatotic effects of a high fructose diet which enhances de novo lipogenesis (DNL) and TG accumulation in the liver (13) are exacerbated by CD36 deletion (14) .
In humans with nonalcoholic fatty liver disease (NAFLD) hepatic CD36 positively correlates with liver fat content (15) suggests that its impact on hepatic FA metabolism might not be limited to enhancing FA flux and TG accumulation. NAFLD is typically characterized by increased output of TG in VLDL without parallel increases in VLDL-apoB output (16) . However, our recent genetic studies associated CD36 level with serum apoprotein-B (apoB) and with VLDL particle number in addition to VLDL-TG (17). These findings suggest a potentially significant influence of CD36 on VLDL secretion in humans.
Recent data documented the role of CD36-mediated signaling in FA metabolism via affecting cellular calcium (18, 19) and the MAPK ERK1/2 pathway (20, 21) . An important consequence of CD36's ability to signal to intracellular calcium was its regulation of the formation and release of prostaglandins (PG) (20) , bioactive compounds with pleiotropic effects that include inhibition of hepatic VLDL secretion (22, 23) . In addition to PG, CD36 influences a number of other secretory events including FA-triggered release of neurotransmitters in taste bud cells (18) , FAinduced insulin secretion by pancreatic islets (24) fat-induced chylomicron secretion by enterocytes (7) and FA-induced release of gut peptides by enteroendocrine cells (8) . A possible role of hepatic CD36 in VLDL secretion remains unexplored.
In the present study, we examined the role of CD36 deficiency on hepatic TG stores, TG and apoB output and PG formation in CD36 knockout (CD36 -/-) and wild type (WT) mice. We also determined the impact of CD36 deletion on hepatic steatosis in the ob/ob mouse deficient in the satiety factor leptin (25) . The ob/ob mouse is hyperphagic and spontaneously develops obesity and fatty liver. Enhanced DNL plays an important role in the steatosis of the ob/ob mouse (26, 27) and is reversed by inhibiting activation of the master lipogenic regulators, the SREBPs (27) Overall, our findings document a novel role of CD36 in the regulation of hepatic PG levels and VLDL secretion which might have relevance to some forms of fatty liver. C-acetic-acid (2µCi/ml). Liver slices were washed in cold PBS and homogenates were counted for radioactivity (Betafluor, National Diagnostics, Atlanta, GA).
Hepatic triglyceride and apoB secretion and microsomal triglyceride protein (MTTP)
activity. Overnight fasted mice were injected with Triton WR 1339 (Tyloxapol), blood samples were collected at baseline and 3h after injection and analyzed forserum TG content (Wako Chemicals USA, Inc). In vivo apo B secretion was determined as described previously (28) .
Briefly, 5h fasted mice were injected with Triton WR 1339 and 2 hours later blood was collected in tubes containing protease inhibitors. The lipoprotein fraction (d<1.063 g/ml) was isolated from equal serum volumes by ultracentrifugation at 100,000 rpm for 4h at 10ºC. SDS-gels. MTTP activity was assayed as described (29) .
Hepatic PG levels: Mice fasted for 5h were administered intragastrically 1/1 olive oil/corn oil (16.5µl/g body weight). Hepatic PG levels were determined 3h later. Briefly, liver lipid extracts (chloroform/methanol, 2:1) with added (20ng) PG standards (PGF2α-d4, PGE2-d4, PGD2-d4) (Cayman Chemical Co. Ann Arbor, MI) were subjected to oximation with OMethoxyamine-HCL in NaOAc followed by derivatization with pentafluorobenxyl bromide in acetonitrile and BSTFA/TMCS for gas chromatography-mass spectroscopy (GC-MS). Areas of native compound to standard were used for computing relative PG levels.
Liver Histology. Tissue fixed in 10% formalin and embedded in paraffin was stained for CD36. Increased hepatic prostaglandins (PG) levels with CD36 deficiency reduce VLDL secretion. CD36 signaling regulates calcium activated release of arachidonic acid and PG formation (20) . Liver PG produced under normal or pathological conditions modulate hepatocyte function (33) . The major liver PG; PGD2, PGF2 and PGE2 were reported to reduce VLDL secretion and increase hepatocyte TG content (22, 23) . We investigated the effect of CD36 deficiency on hepatic PG levels 3h after intragastric oil administration (16.5µl/g body weight).
Levels of the three major hepatic prostaglandins PGF2, PGD2 and PGE2 were significantly higher in livers from CD36 -/-as compared to WT mice ( Fig. 2A) . The increase in hepatic PG appeared to reflect higher arachidonic acid (AA) content ( Fig. 2B ) and higher protein levels of the key cyclooxygenase enzyme cox-1 (Fig. 2C) . Levels of cox-2 also trended higher without reaching significance (Fig. 2D) . Staining of liver sections for cox1 (Fig. 2E) showed a clear increase in its levels in livers from CD36 -/-mice and the increase primarily occurred in hepatocyte sinusoids indicating it involves Kuppfer cells or macrophages.
We next examined whether the altered PG formation contributes to the impaired VLDL secretion by livers from CD36 -/-mice. TG secretion by liver slices was assayed in presence or absence of inhibitors of PG synthesis. Liver slices were incubated in control medium (CT) or in medium containing 10µM cyclooxygenase inhibitors, SC560 for cox-1 and SC-236 for cox-2.
Both inhibitors modestly (1.4-1.7 fold) augmented TG secretion by liver slices from WT mice (Fig. 2F) . On the other hand the inhibitors had much more pronounced effects on TG secretion by liver slices from CD36 -/-mice, which was increased 8 fold by the cox-1 inhibitor SC-560 and 5 fold by the cox-2 inhibitor SC-236 (Fig. 2F) . Together, these data documented that CD36 deletion reduces VLDL secretion at least in part via altering hepatic PG levels. CD36 deletion Reduced VLDL secretion with cd36 deficiency exacerbates hepatic steatosis in ob/ob mice.
We next sought to determine whether the effect of CD36 deficiency to reduce VLDL secretion could impact hepatic steatosis under certain metabolic conditions. We chose the leptin deficient hyperphagic ob/ob mouse, a commonly used animal model of obesity (25) for two major reasons.
First, as in human NAFLD (34) , hepatic steatosis in the ob/ob mouse is obesity-associated, spontaneous and characterized by enhanced de novo lipogenesis (DNL) (26, 27) . Second, increased fatty acid uptake by hepatocytes was reported not to be a major contributor to the steatosis in this model (35) in contrast to other experimental models of hepatic steatosis (12) .
Homozygous ob/ob mice lacking CD36 (ob-CD36
-/-) were generated and studied for hepatic TG accumulation and VLDL secretion.
CD36 deficiency aggravates hepatic lipid accumulation in ob/ob mice. ob-CD36
-/-mice knockout for both CD36 and leptin had ~30% lower body weight than ob/ob mice (Fig. 3A) .
Serum TG (Fig. 3B) and glucose ( Fig. 3C) were reduced (30% and 40%, respectively) and insulin ( Fig. 3D ) was 6 fold lower in ob-CD36 -/-mice as compared to ob/ob mice. The impaired glucose tolerance of ob-ob mice was dramatically improved by CD36 deletion (Fig. 3E) . Liver to body weight ratios of ob-CD36 -/-mice were comparable to those of ob/ob mice (Fig. 3F) .
However, ob-CD36 -/-livers appeared fatty (Fig. 3G) and this was confirmed by measuring hepatic TG content which was ~1.7-fold higher in ob-CD36 -/-as compared to ob/ob mice (Fig.   3H ).
Livers of ob/ob mice had 20-fold more CD36 mRNA than WT as was previously reported (35) (Fig. 4A ) and this was paralleled by sixfold higher CD36 protein levels (Fig. 4B) . In WT by guest, on November 10, 2017
www.jlr.org Downloaded from livers, CD36 staining was detectable on hepatocytes (arrow) but was mostly present in sinusoids indicative of localization on Kupffer cells (Fig. 4C) . CD36 distribution was similar in ob/ob livers but CD36 staining was more intense (Fig. 4C) . Immunofluorescence staining of liver sections (Fig. 4D) Oil-Red-O staining documented widespread lipid deposition in ob/ob and ob-CD36 -/-livers (Fig. 4E) . Electron microscopy showed coalesced cytoplasmic vacuoles reaching 30 microns in ob/ob hepatocytes that pressed the nucleus toward the periphery (Fig. 4F a-b , contiguous or single cells, respectively). In contrast, hepatocytes from ob-CD36 -/- (Fig. 4F c-d , contiguous or single cells) had multiple small and heterogeneous lipid droplets, (LD average 5 microns).
Perilipins (PLIN) (1-5) surround LD playing a role in LD maturation and metabolism (36, 37) . We examined content or distribution of LD proteins. PLIN2, the most abundant hepatic PLIN was upregulated in ob/ob with further increases in ob-CD36 -/-livers where it highlighted the smaller LD size (Fig. 4G-H ). PLIN1 and PLIN5 were also upregulated in ob-CD36 -/-as compared to ob/ob livers while PLIN3 was not altered (Fig. 4G) (Fig. 5B) . Further, liver slices from ob/ob and ob-CD36 -/-mice incubated in vitro with 14 C-acetate showed similar label incorporation into lipid (Fig. 5C) . Palmitate oxidation by liver slices from ob/ob and ob-CD36 -/-mice was similar (data not shown).
We next examined the effect of CD36 deletion on VLDL secretion in ob/ob mice. In vivo TG secretion in overnight fasted mice given Triton WR1339 was reduced by 50% in ob-CD36
-/-as compared to ob/ob mice (Fig. 5D) . Furthermore, TG and apoB secretion using liver slices, incubated in vitro, was similarly reduced (Fig. 5E) . Activity (Fig. 5G ) and gene expression (data not shown) of MTTP did not change. Expression of DGAT1 and DGAT2 was similar for livers of ob/ob and ob-CD36 -/-mice. Expression of PPARγ and protein levels of FA synthase were increased in ob/ob mice but were not significantly altered by CD36 deletion (Supplemental Fig.   1 ).
As shown earlier in lean CD36 -/-mice, levels of PGF2, PGD2 and PGE2 were significantly higher in ob-CD36 -/-as compared to ob/ob mice (Fig. 6A) . The increase in hepatic PG in ob-CD36 -/-mice appeared to reflect higher arachidonic acid content (data not shown) and higher protein levels of the key cyclooxygenase enzyme cox-2 (Fig. 6B) . Levels of cox1 trended higher without reaching significance (Fig. 6C) . Immunofluorescence staining for the cyclooxygenases cox-1 (red) and cox-2 (green) showed localization of both enzymes to macrophage/kupffer cells in liver sinusoids with higher staining in ob-CD36 -/-liver sections (Fig. 6D) . This is consistent with the higher hepatic expression and protein levels of these enzymes with CD36 deletion (Fig. 
6B-C).
The response of TG secretion to inhibitors of PG synthesis was examined next using liver slices. The cox inhibitors, SC-560 and SC-236, strongly augmented secretion from ob-CD36
-/-slices (5 and 8 folds) with much smaller (<2fold) effects on secretion from ob/ob slices (Fig.   6E ).
These data indicated that alterations in hepatic PG levels as a result of CD36 deficiency reduce VLDL secretion and aggravate hepatic steatosis in ob/ob mice. The reduced TG output is consistent with the low fasting serum TG levels measured in ob-CD36 -/-mice (Fig. 3B) . In addition the findings suggest that CD36 deletion increases PG production by macrophage/kupffer cells and this in turn reduces VLDL secretion by hepatocytes.
DISCUSSION
In addition to functioning in FA uptake, CD36 has signal transduction capabilities that influence a number of secretory events including chylomicron secretion by enterocytes (7, 21) , In rat hepatocytes, PGE2, PGD2 or PGF2 were shown to suppress both VLDL-apoB and TG output and to increase hepatocyte lipid content (22, 23) . Furthermore, Kupffer cell-derived PGE2 has been implicated in alcohol-induced steatosis in rat liver (40) . Despite their importance to hepatic lipid metabolism, little is known about the factors regulating PG production. Our data implicate CD36 in hepatic PG formation, consistent with our earlier report showing that CD36 signaling acutely regulates Ca 2+ activated arachidonic acid release by phospholipases (20) .
Livers from CD36 -/-mice indeed have upregulation of cyclooxygenase enzymes and enhanced PG production (Fig. 2) similar to peritoneal macrophages from these mice (20) .
VLDL production has been reported to be influenced by cellular calcium metabolism (22, 41, 42) which regulates phospholipid turnover (43, 44) . Enhanced phospholipid de-acylation associates with VLDL production and might be important for sorting the lipid to the secretory pool and/or for VLDL particle maturation (45-47). CD36-mediated signaling influences phospholipase activation and phospholipid remodeling (19, 20, 48) resulting in the generation of PG with additional effects on ionic flux and lipid turnover (49, 50) . Thus CD36 expression in the liver might play dual roles; it facilitates FA flux under conditions of high FA supply (11, 12) and it transduces intracellular signals that regulate phospholipid de-acylation and eicosanoid production, events that would influence assembly and secretion of VLDL particles. Future by guest, on November 10, 2017
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Interestingly, the inhibition of VLDL secretion in the CD36 fatty liver associated with a microvesicular pattern of steatosis and further study is needed to understand the mechanism involved and whether it can be related to the altered expression of the various perilipins.
Microvesicular steatosis has been previously reported under conditions of altered fatty acid metabolism (52, 53).
The marked increase in CD36 mRNA in livers of ob/ob compared to WT mice has been described previously (10, 35), a finding we confirmed and extended to protein levels. However, this increase is unlikely to contribute to hepatic steatosis of ob/ob mice since steatosis was not reversed but was rather exacerbated by CD36 deletion. We believe this would reflect the significant contribution of lipogenesis to hepatic steatosis in the ob/ob mouse, as demonstrated recently (27) . Interestingly, FA uptake was not increased in hepatocytes isolated from ob/ob mice while increases were measured in hepatocytes from mice fed high fat or administered ethanol (35) . Our data suggest that a major part of the increase in CD36 expression observed in ob/ob livers involves Kupffer cells and macrophages as opposed to hepatocytes, although the latter might be more involved in high fat fed mice (11, 35) .
In summary, this study described the novel finding that CD36 deletion inhibits VLDL secretion by enhancing hepatic prostaglandin formation. The studies with ob/ob mice deficient in CD36 showed that the net impact of CD36 on hepatic steatosis might differ depending on the metabolic context. While deletion protects from high fat induced steatosis where FA uptake is a major contributor (11) Relevance to humans -NAFLD is a frequent and major complication of obesity in humans (16) . In NAFLD there is dysfunction of the factors balancing liver supply of fatty acids from plasma and from endogenous lipogenesis with hepatic lipid utilization and output through VLDL secretion (54, 55) . Liver CD36 levels are normally low and hepatic fatty acid uptake, in contrast to myocardial uptake, is independent of CD36 (56). However, CD36 levels are increased in NAFLD where they correlate with hepatic liver content (15, 57, 58) . We propose that the increase in CD36 level in NAFLD might be in part an adaptation to increase VLDL secretion under conditions of lipid accumulation. Our previous genetic association study documented a positive relationship between CD36 protein expression on monocytes and serum levels of VLDL-apoB and the number of VLDL particles in addition to VLDL-TG (17). This together with the data from the current study strongly supports relevance of hepatic CD36 to VLDL secretion in humans. The liver of the obese human with NAFLD derives the major part of FA for VLDL-TG via uptake from the circulating fatty acid pool and about one third from endogenous FA synthesis (59) . Hepatic DNL is especially enhanced under conditions of high carbohydrate intake (13) and under such conditions the influence of CD36 on VLDL secretion might predominate as compared to its effect on hepatic FA uptake. It would be informative to determine how CD36 deficiency in humans influences the response of hepatic lipid metabolism to high carbohydrate as compared to high fat intake. Data are means ± se, *P<0.05, ***P<0.001. by guest, on November 10, 2017
